Comparison of CVF (Cyclophosphamide+Vinorelbine+5-Fluorouracil) and CMF (Cyclophosphamide+Methotrexate+5-Fluorouracil) Adjuvant Chemotherapy in Early Breast Cancer
Our study aimed to evaluate the feasibility of adjuvant cyclophosphamide/vinorelbine/5-fluorourail (CVF) chemotherapy as an alternative to cyclophosphamide/methotrexate/5-fluorouracil (CMF) chemotherapy for treating early breast cancer. One hundred and forty-nine patients were randomly assigned to C...
Saved in:
Published in | Journal of breast cancer Vol. 14; no. 3; pp. 223 - 228 |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Korea (South)
Korean Breast Cancer Society
01.09.2011
한국유방암학회 |
Subjects | |
Online Access | Get full text |
ISSN | 1738-6756 2092-9900 2092-9900 |
DOI | 10.4048/jbc.2011.14.3.223 |
Cover
Abstract | Our study aimed to evaluate the feasibility of adjuvant cyclophosphamide/vinorelbine/5-fluorourail (CVF) chemotherapy as an alternative to cyclophosphamide/methotrexate/5-fluorouracil (CMF) chemotherapy for treating early breast cancer.
One hundred and forty-nine patients were randomly assigned to CMF or CVF adjuvant chemotherapy for treating their early stage breast cancer between September 2000 and December 2007. The disease-free survival (DFS), the overall survival (OS), and the toxicity profiles of both groups were compared.
Sixty-seven patients underwent CMF chemotherapy whereas 82 patients underwent CVF chemotherapy. The DFS and OS were 88 months (95% confidence interval [CI], 76-101 months) and 94 months (95% CI, 83-104 months), respectively for the CMF group, and 97 months (95% CI, 93-101 months), and 101 months (95% CI, 98-104 months), respectively for the CVF group. However, those survival gains of the CVF group were not statistically significant (p-value=0.069 for the DFS and 0.99 for the OS). The CVF group showed a favorable toxicity profile in terms of the grade 3/4 hematologic toxicities as compared to that of the CMF group.
Clinical outcome of CVF chemotherapy was comparable to CMF with a favorable toxicity profiles. However, it is difficult to conclude the feasibility of CVF regimen because of small number of studied patients. |
---|---|
AbstractList | Our study aimed to evaluate the feasibility of adjuvant cyclophosphamide/vinorelbine/5-fluorourail (CVF) chemotherapy as an alternative to cyclophosphamide/methotrexate/5-fluorouracil (CMF) chemotherapy for treating early breast cancer.
One hundred and forty-nine patients were randomly assigned to CMF or CVF adjuvant chemotherapy for treating their early stage breast cancer between September 2000 and December 2007. The disease-free survival (DFS), the overall survival (OS), and the toxicity profiles of both groups were compared.
Sixty-seven patients underwent CMF chemotherapy whereas 82 patients underwent CVF chemotherapy. The DFS and OS were 88 months (95% confidence interval [CI], 76-101 months) and 94 months (95% CI, 83-104 months), respectively for the CMF group, and 97 months (95% CI, 93-101 months), and 101 months (95% CI, 98-104 months), respectively for the CVF group. However, those survival gains of the CVF group were not statistically significant (p-value=0.069 for the DFS and 0.99 for the OS). The CVF group showed a favorable toxicity profile in terms of the grade 3/4 hematologic toxicities as compared to that of the CMF group.
Clinical outcome of CVF chemotherapy was comparable to CMF with a favorable toxicity profiles. However, it is difficult to conclude the feasibility of CVF regimen because of small number of studied patients. Our study aimed to evaluate the feasibility of adjuvant cyclophosphamide/vinorelbine/5-fluorourail (CVF) chemotherapy as an alternative to cyclophosphamide/methotrexate/5-fluorouracil (CMF) chemotherapy for treating early breast cancer.PURPOSEOur study aimed to evaluate the feasibility of adjuvant cyclophosphamide/vinorelbine/5-fluorourail (CVF) chemotherapy as an alternative to cyclophosphamide/methotrexate/5-fluorouracil (CMF) chemotherapy for treating early breast cancer.One hundred and forty-nine patients were randomly assigned to CMF or CVF adjuvant chemotherapy for treating their early stage breast cancer between September 2000 and December 2007. The disease-free survival (DFS), the overall survival (OS), and the toxicity profiles of both groups were compared.METHODSOne hundred and forty-nine patients were randomly assigned to CMF or CVF adjuvant chemotherapy for treating their early stage breast cancer between September 2000 and December 2007. The disease-free survival (DFS), the overall survival (OS), and the toxicity profiles of both groups were compared.Sixty-seven patients underwent CMF chemotherapy whereas 82 patients underwent CVF chemotherapy. The DFS and OS were 88 months (95% confidence interval [CI], 76-101 months) and 94 months (95% CI, 83-104 months), respectively for the CMF group, and 97 months (95% CI, 93-101 months), and 101 months (95% CI, 98-104 months), respectively for the CVF group. However, those survival gains of the CVF group were not statistically significant (p-value=0.069 for the DFS and 0.99 for the OS). The CVF group showed a favorable toxicity profile in terms of the grade 3/4 hematologic toxicities as compared to that of the CMF group.RESULTSSixty-seven patients underwent CMF chemotherapy whereas 82 patients underwent CVF chemotherapy. The DFS and OS were 88 months (95% confidence interval [CI], 76-101 months) and 94 months (95% CI, 83-104 months), respectively for the CMF group, and 97 months (95% CI, 93-101 months), and 101 months (95% CI, 98-104 months), respectively for the CVF group. However, those survival gains of the CVF group were not statistically significant (p-value=0.069 for the DFS and 0.99 for the OS). The CVF group showed a favorable toxicity profile in terms of the grade 3/4 hematologic toxicities as compared to that of the CMF group.Clinical outcome of CVF chemotherapy was comparable to CMF with a favorable toxicity profiles. However, it is difficult to conclude the feasibility of CVF regimen because of small number of studied patients.CONCLUSIONClinical outcome of CVF chemotherapy was comparable to CMF with a favorable toxicity profiles. However, it is difficult to conclude the feasibility of CVF regimen because of small number of studied patients. Purpose: Our study aimed to evaluate the feasibility of adjuvant cyclophosphamide/vinorelbine/5-fluorourail (CVF) chemotherapy as an alternative to cyclophosphamide/methotrexate/5-fluorouracil (CMF) chemotherapy for treating early breast cancer. Methods: One hundred and forty-nine patients were randomly assigned to CMF or CVF adjuvant chemotherapy for treating their early stage breast cancer between September 2000 and December 2007. The disease-free survival (DFS), the overall survival (OS), and the toxicity profiles of both groups were compared. Results: Sixty-seven patients underwent CMF chemotherapy whereas 82 patients underwent CVF chemotherapy. The DFS and OS were 88 months (95% confidence interval [CI], 76-101 months) and 94 months (95% CI, 83-104 months), respectively for the CMF group, and 97 months (95% CI, 93-101 months), and 101 months (95% CI, 98-104 months), respectively for the CVF group. However, those survival gains of the CVF group were not statistically significant (p-value=0.069 for the DFS and 0.99 for the OS). The CVF group showed a favorable toxicity profile in terms of the grade 3/4 hematologic toxicities as compared to that of the CMF group. Conclusion: Clinical outcome of CVF chemotherapy was comparable to CMF with a favorable toxicity profiles. However, it is difficult to conclude the feasibility of CVF regimen because of small number of studied patients. KCI Citation Count: 0 |
Author | Cho, Hyunjin Gwak, Geumhee Kim, Young Duk Bae, Byung Noe Kim, Hong Ju Shin, Eunah Kim, Ki Whan Park, Kyeongmee Yang, Keun Ho Kim, Ji-Young Han, Sehwan Kim, Hongyong Park, Sung-Jin |
AuthorAffiliation | 4 Department of Surgery, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea 3 Department of Surgery, Ilsan Hospital, Dongguk University College of Medicine, Goyang, Korea 2 Department of Radiology, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea Department of Surgery, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea 1 Department of Pathology, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea |
AuthorAffiliation_xml | – name: 4 Department of Surgery, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea – name: Department of Surgery, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea – name: 1 Department of Pathology, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea – name: 3 Department of Surgery, Ilsan Hospital, Dongguk University College of Medicine, Goyang, Korea – name: 2 Department of Radiology, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea |
Author_xml | – sequence: 1 givenname: Geumhee surname: Gwak fullname: Gwak, Geumhee organization: Department of Surgery, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea – sequence: 2 givenname: Kyeongmee surname: Park fullname: Park, Kyeongmee organization: Department of Pathology, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea – sequence: 3 givenname: Eunah surname: Shin fullname: Shin, Eunah organization: Department of Pathology, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea – sequence: 4 givenname: Sehwan surname: Han fullname: Han, Sehwan organization: Department of Surgery, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea – sequence: 5 givenname: Ji-Young surname: Kim fullname: Kim, Ji-Young organization: Department of Radiology, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea – sequence: 6 givenname: Hongyong surname: Kim fullname: Kim, Hongyong organization: Department of Surgery, Ilsan Hospital, Dongguk University College of Medicine, Goyang, Korea – sequence: 7 givenname: Young Duk surname: Kim fullname: Kim, Young Duk organization: Department of Surgery, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea – sequence: 8 givenname: Hong Ju surname: Kim fullname: Kim, Hong Ju organization: Department of Surgery, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea – sequence: 9 givenname: Ki Whan surname: Kim fullname: Kim, Ki Whan organization: Department of Surgery, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea – sequence: 10 givenname: Byung Noe surname: Bae fullname: Bae, Byung Noe organization: Department of Surgery, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea – sequence: 11 givenname: Keun Ho surname: Yang fullname: Yang, Keun Ho organization: Department of Surgery, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea – sequence: 12 givenname: Hyunjin surname: Cho fullname: Cho, Hyunjin organization: Department of Surgery, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea – sequence: 13 givenname: Sung-Jin surname: Park fullname: Park, Sung-Jin organization: Department of Surgery, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22031805$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART001591211$$DAccess content in National Research Foundation of Korea (NRF) |
BookMark | eNqNkctu1DAUhi1URKeFB2CDsqOoSji-5OIN0hB1oFIrJDTq1nISh3jq2KmdFPI8vCgZptwEC1Zncf7LOfpO0JF1ViH0HEPCgBWvd1WdEMA4wSyhCSH0EVoR4CTmHOAIrXBOizjL0-wYnYSwA8gYzfMn6JgQoLiAdIW-lq4fpNfB2ci1UXmzic7KuTZu6FwYOtnrRp3faOu8MpW26jyNN2Zy3k1e1tq8iqRtovL6X65rNXZu9OqLHP-2rZvddC_tGJWd6t3YKS-HOdI2upDezNFbr2RYltLWyj9Fj1tpgnr2ME_RdnOxLd_HVx_eXZbrq7imBR1jDLyQeQW8LjhRVZO3-29Z1vIsA8Zz0lBOZApNBm1D01ZizjgtSJtnRZUTeorODrHWt-K21sJJ_X1-cuLWi_XH7aVgPCsIXqTkIJ3sIOfP0hgxeN1LPwsMYs9GLGzEno3ATFCxsFlMbw6mYap61dTKjl7-Mu7b_txY3S3d94ISgBTzJeDlQ4B3d5MKo-h1qJUx0io3BcEBAwBLYVG--L3qZ8cP7osAHwS1dyF41f7H_d8ALs7CDg |
Cites_doi | 10.1200/JCO.1995.13.11.2722 10.1093/annonc/mdi276 10.1007/BF01805984 10.1080/02841860310004373 10.1200/JCO.2004.11.503 10.1016/S0140-6736(05)66544-0 10.1200/JCO.1993.11.7.1245 10.4048/jkbcs.2004.7.4.289 10.1200/JCO.1994.12.10.2094 10.1200/JCO.1995.13.12.2886 10.1200/JCO.1990.8.9.1483 10.1200/JCO.2005.09.423 10.1159/000216938 10.1159/000163056 10.1093/jnci/djn085 10.1136/bmj.38314.622095.8F 10.1007/s10549-004-1001-0 10.1038/sj.bjc.6603773 10.7326/0003-4819-89-1-107 10.2174/187152008785914798 10.1093/jnci/djp092 |
ContentType | Journal Article |
Copyright | 2011 Korean Breast Cancer Society 2011 |
Copyright_xml | – notice: 2011 Korean Breast Cancer Society 2011 |
DBID | AAYXX CITATION NPM 7X8 5PM ADTOC UNPAY ACYCR |
DOI | 10.4048/jbc.2011.14.3.223 |
DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall Korean Citation Index |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2092-9900 |
EndPage | 228 |
ExternalDocumentID | oai_kci_go_kr_ARTI_496821 10.4048/jbc.2011.14.3.223 PMC3200519 22031805 10_4048_jbc_2011_14_3_223 |
Genre | Journal Article |
GroupedDBID | --- 5-W 5GY 8JR 8XY 9ZL AAYXX ADBBV ADRAZ AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL CITATION DIK DU5 EF. GROUPED_DOAJ HYE KQ8 M48 O5R O5S PGMZT RPM NPM 7X8 5PM ADTOC UNPAY ACYCR |
ID | FETCH-LOGICAL-c383t-1098a7b09c892ebd7f437746f96604972d392a50d60fd35fa1949382f768b723 |
IEDL.DBID | M48 |
ISSN | 1738-6756 2092-9900 |
IngestDate | Tue Nov 21 21:30:10 EST 2023 Tue Aug 19 19:21:49 EDT 2025 Thu Aug 21 18:08:20 EDT 2025 Fri Jul 11 08:46:31 EDT 2025 Mon Jul 21 05:55:37 EDT 2025 Tue Jul 01 01:56:40 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | Adjuvant chemotherapy Cyclophosphamide Breast neoplasms Methotrexate Vinorelbine Fluorouracil |
Language | English |
License | This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. cc-by-nc |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c383t-1098a7b09c892ebd7f437746f96604972d392a50d60fd35fa1949382f768b723 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 G704-SER000010237.2011.14.3.007 |
OpenAccessLink | https://proxy.k.utb.cz/login?url=http://ejbc.kr/Synapse/Data/PDFData/0096JBC/jbc-14-223.pdf |
PMID | 22031805 |
PQID | 901000450 |
PQPubID | 23479 |
PageCount | 6 |
ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_496821 unpaywall_primary_10_4048_jbc_2011_14_3_223 pubmedcentral_primary_oai_pubmedcentral_nih_gov_3200519 proquest_miscellaneous_901000450 pubmed_primary_22031805 crossref_primary_10_4048_jbc_2011_14_3_223 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2011-09-01 |
PublicationDateYYYYMMDD | 2011-09-01 |
PublicationDate_xml | – month: 09 year: 2011 text: 2011-09-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Korea (South) |
PublicationPlace_xml | – name: Korea (South) |
PublicationTitle | Journal of breast cancer |
PublicationTitleAlternate | J Breast Cancer |
PublicationYear | 2011 |
Publisher | Korean Breast Cancer Society 한국유방암학회 |
Publisher_xml | – name: Korean Breast Cancer Society – name: 한국유방암학회 |
References | Tancini (10.4048/jbc.2011.14.3.223_ref6) 1979; 2 Slamon (10.4048/jbc.2011.14.3.223_ref21) 2009; 101 Chua (10.4048/jbc.2011.14.3.223_ref13) 2005; 16 von Minckwitz (10.4048/jbc.2011.14.3.223_ref25) 2008; 100 Cosse (10.4048/jbc.2011.14.3.223_ref2) 2008; 8 Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (10.4048/jbc.2011.14.3.223_ref23) 2005; 365 Weber (10.4048/jbc.2011.14.3.223_ref14) 1995; 13 Julka (10.4048/jbc.2011.14.3.223_ref4) 1999; 47 Bonadonna (10.4048/jbc.2011.14.3.223_ref5) 1978; 48 Kerbrat (10.4048/jbc.2011.14.3.223_ref17) 2007; 96 Gasparini (10.4048/jbc.2011.14.3.223_ref11) 1994; 12 Elomaa (10.4048/jbc.2011.14.3.223_ref15) 2003; 42 Heys (10.4048/jbc.2011.14.3.223_ref3) 2005; 90 Vici (10.4048/jbc.2011.14.3.223_ref16) 2008; 75 Fisher (10.4048/jbc.2011.14.3.223_ref19) 1990; 8 Ardavanis (10.4048/jbc.2011.14.3.223_ref24) 1998; 12 Valero (10.4048/jbc.2011.14.3.223_ref20) 1995; 13 Bonadonna (10.4048/jbc.2011.14.3.223_ref7) 1985; 5 Ejlertsen (10.4048/jbc.2011.14.3.223_ref12) 2004; 22 Cho (10.4048/jbc.2011.14.3.223_ref18) 2004; 7 Levine (10.4048/jbc.2011.14.3.223_ref22) 2005; 23 Krikorian (10.4048/jbc.2011.14.3.223_ref9) 1991; 14 Fumoleau (10.4048/jbc.2011.14.3.223_ref10) 1993; 11 Bonadonna (10.4048/jbc.2011.14.3.223_ref8) 2005; 330 Shackney (10.4048/jbc.2011.14.3.223_ref1) 1978; 89 |
References_xml | – volume: 13 start-page: 2722 year: 1995 ident: 10.4048/jbc.2011.14.3.223_ref14 publication-title: J Clin Oncol doi: 10.1200/JCO.1995.13.11.2722 – volume: 16 start-page: 1435 year: 2005 ident: 10.4048/jbc.2011.14.3.223_ref13 publication-title: Ann Oncol doi: 10.1093/annonc/mdi276 – volume: 5 start-page: 95 year: 1985 ident: 10.4048/jbc.2011.14.3.223_ref7 publication-title: Breast Cancer Res Treat doi: 10.1007/BF01805984 – volume: 2 start-page: 285 year: 1979 ident: 10.4048/jbc.2011.14.3.223_ref6 publication-title: Cancer Clin Trials – volume: 42 start-page: 309 year: 2003 ident: 10.4048/jbc.2011.14.3.223_ref15 publication-title: Acta Oncol doi: 10.1080/02841860310004373 – volume: 22 start-page: 2313 year: 2004 ident: 10.4048/jbc.2011.14.3.223_ref12 publication-title: J Clin Oncol doi: 10.1200/JCO.2004.11.503 – volume: 365 start-page: 1687 year: 2005 ident: 10.4048/jbc.2011.14.3.223_ref23 publication-title: Lancet doi: 10.1016/S0140-6736(05)66544-0 – volume: 11 start-page: 1245 year: 1993 ident: 10.4048/jbc.2011.14.3.223_ref10 publication-title: J Clin Oncol doi: 10.1200/JCO.1993.11.7.1245 – volume: 7 start-page: 289 year: 2004 ident: 10.4048/jbc.2011.14.3.223_ref18 publication-title: J Korean Breast Cancer Soc doi: 10.4048/jkbcs.2004.7.4.289 – volume: 12 start-page: 2094 year: 1994 ident: 10.4048/jbc.2011.14.3.223_ref11 publication-title: J Clin Oncol doi: 10.1200/JCO.1994.12.10.2094 – volume: 13 start-page: 2886 year: 1995 ident: 10.4048/jbc.2011.14.3.223_ref20 publication-title: J Clin Oncol doi: 10.1200/JCO.1995.13.12.2886 – volume: 8 start-page: 1483 year: 1990 ident: 10.4048/jbc.2011.14.3.223_ref19 publication-title: J Clin Oncol doi: 10.1200/JCO.1990.8.9.1483 – volume: 23 start-page: 5166 year: 2005 ident: 10.4048/jbc.2011.14.3.223_ref22 publication-title: J Clin Oncol doi: 10.1200/JCO.2005.09.423 – volume: 14 start-page: 7 year: 1991 ident: 10.4048/jbc.2011.14.3.223_ref9 publication-title: Onkologie doi: 10.1159/000216938 – volume: 75 start-page: 175 year: 2008 ident: 10.4048/jbc.2011.14.3.223_ref16 publication-title: Oncology doi: 10.1159/000163056 – volume: 100 start-page: 542 year: 2008 ident: 10.4048/jbc.2011.14.3.223_ref25 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djn085 – volume: 330 start-page: 217 year: 2005 ident: 10.4048/jbc.2011.14.3.223_ref8 publication-title: BMJ doi: 10.1136/bmj.38314.622095.8F – volume: 90 start-page: 169 year: 2005 ident: 10.4048/jbc.2011.14.3.223_ref3 publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-004-1001-0 – volume: 96 start-page: 1633 year: 2007 ident: 10.4048/jbc.2011.14.3.223_ref17 publication-title: Br J Cancer doi: 10.1038/sj.bjc.6603773 – volume: 89 start-page: 107 year: 1978 ident: 10.4048/jbc.2011.14.3.223_ref1 publication-title: Ann Intern Med doi: 10.7326/0003-4819-89-1-107 – volume: 8 start-page: 790 year: 2008 ident: 10.4048/jbc.2011.14.3.223_ref2 publication-title: Anticancer Agents Med Chem doi: 10.2174/187152008785914798 – volume: 47 start-page: 499 year: 1999 ident: 10.4048/jbc.2011.14.3.223_ref4 publication-title: J Assoc Physicians India – volume: 101 start-page: 615 year: 2009 ident: 10.4048/jbc.2011.14.3.223_ref21 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djp092 – volume: 12 start-page: 559 year: 1998 ident: 10.4048/jbc.2011.14.3.223_ref24 publication-title: In Vivo – volume: 48 start-page: 659 year: 1978 ident: 10.4048/jbc.2011.14.3.223_ref5 publication-title: Arch Geschwulstforsch |
SSID | ssj0064377 |
Score | 1.8289342 |
Snippet | Our study aimed to evaluate the feasibility of adjuvant cyclophosphamide/vinorelbine/5-fluorourail (CVF) chemotherapy as an alternative to... Purpose: Our study aimed to evaluate the feasibility of adjuvant cyclophosphamide/vinorelbine/5-fluorourail (CVF) chemotherapy as an alternative to... |
SourceID | nrf unpaywall pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 223 |
SubjectTerms | Original 일반외과학 |
SummonAdditionalLinks | – databaseName: Unpaywall dbid: UNPAY link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1db9MwFLVYJwEvfA_Cl4zEAzAlTW0nTR67jGpM6jSJbRriwbJjh2YNSZQmgvJ3-KNcp2mh6iQEUqQ8xI5l59j33Pj6XIReU6YCzxfUprF0baZCactQwmIoAun7CVxt_pTJiX90zo4vvcvfUZX6SsbOrOp_XOSinOv-oahF__Rw3N4N3T4-iPpQxh4wGwybU6pkB-36ZnOph3bPT05Hn9oTkDCLgQm3meXckNiw5HZbmszo1JpGWvHOAXOoQwjdMEo7eZVcxze3wyZvNXkpFt9Elv1hk8Z30efVyZ5lKMrMaWrpxD-2hR7_o7v30J2OquLRElv30Q2dP0A3J91m_EP0M1rnMMRFgqOLMX4TLeKsKKfFvJyKr6nS-xdpXlQ6k4bMevY4a4oK3iviNHuLRa5wNLmu1sTkta4r_R2Y8Fa1kbpqgP_X2IgddAfIFjjNcSvWjA9MmD08NHCuHqGz8fuz6Mjucj7YMfjKNViFMBBD6YZxEBIt1TBhFBiqnxgVURYOiQJCJzxX-W6iqJeIQchCGpAE3CY5JHQP9fIi108QVm6QMOUTGQOFITGVQvieFGAZNDGqeRZ6t_rmvFwqe3DwiAxAOAw5NwABx4hTDiNvoVeACj6LU270uM39S8FnFQev4wNnoR-QgYXwCjMc5qjZeBG5Lpo5NyEwhju7Fnq8hNC6RULMqup6FhpugGtdwDS3-SRPp60MOCUt_7bQ_hqGf-_I038q_QzdXv5DNzF1z1Gvrhr9AkhYLV92s-0Xl78s8Q priority: 102 providerName: Unpaywall |
Title | Comparison of CVF (Cyclophosphamide+Vinorelbine+5-Fluorouracil) and CMF (Cyclophosphamide+Methotrexate+5-Fluorouracil) Adjuvant Chemotherapy in Early Breast Cancer |
URI | https://www.ncbi.nlm.nih.gov/pubmed/22031805 https://www.proquest.com/docview/901000450 https://pubmed.ncbi.nlm.nih.gov/PMC3200519 http://ejbc.kr/Synapse/Data/PDFData/0096JBC/jbc-14-223.pdf https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART001591211 |
UnpaywallVersion | publishedVersion |
Volume | 14 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
ispartofPNX | Journal of Breast Cancer, 2011, 14(3), 55, pp.223-228 |
journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 2092-9900 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0064377 issn: 2092-9900 databaseCode: KQ8 dateStart: 20110101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2092-9900 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0064377 issn: 2092-9900 databaseCode: DOA dateStart: 19980101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 2092-9900 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0064377 issn: 2092-9900 databaseCode: DIK dateStart: 20110101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVERR databaseName: KoreaMed Open Access customDbUrl: eissn: 2092-9900 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0064377 issn: 2092-9900 databaseCode: 5-W dateStart: 20050101 isFulltext: true titleUrlDefault: https://koreamed.org/journals providerName: Korean Association of Medical Journal Editors – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 2092-9900 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0064377 issn: 2092-9900 databaseCode: RPM dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 2092-9900 dateEnd: 20250630 omitProxy: true ssIdentifier: ssj0064377 issn: 2092-9900 databaseCode: M48 dateStart: 20110301 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1ba9swFBa9wLaXsWvnXYIGY2wrDo4s355GZha6gcsemtI9CcmyF7ee7ToOa37P_ujOsR2z0EDB4AdbvuiTjr6jI32HkHc2177jStu0Y2WZXAfKVIECYyh95bopHG3-lOjUPZnz7xfOxR7ZRM_7ClzudO0wn9S8zsc31-vP0OGBv445ys5eqrjT4pzwsT2G8e59dW1iXimMv_ZJNvbJIYxVDNt9xIc4A0atcEM1swJmgl3u4567n7o1cu0XdbqLlN5eW3l_VVRy_Ufm-X8D1-wRedgzTjrtmshjspcUT8i9qI-pPyV_wyEVIS1TGp7P6IdwHedltSiX1UL-znRyfJ4VZZ3kCjmpY87yVVnDc2Wc5R-pLDQNo12lIkxP3dTJDRDaW8Wm-nIFNL6hqFnQ7wNb06ygreYy_YKr5eEitsr6GTmbfT0LT8w-dYMZg8vbgHEPfOkpK4j9gCVKeynWNHdTFAPlgcc08DLpWNq1Um07qZwEPLB9loL3ozxmPycHRVkkLwjVlp9y7TIVAxNhsa2kdB0lwcAnDMXvDPJpg4qoOoEOAY4NQigAQoEQgn8jbAEQGuQt4Cau4kygrDaef5XiqhbgPHwTPHB9NjEI3aAqoKth_EQWSblaClzJghTYMshRB_LwRsbQOFqOQbwt-Icb8HXbV4ps0ap526yl0QY5HhrK3T_y8u6PfEUedPPfuB7uNTlo6lXyBghUo0btxMOo7Qmjdn5rRA7npz-mP_8BIt0dWQ |
linkProvider | Scholars Portal |
linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1db9MwFLVYJwEvfA_Cl4zEAzAlTW0nTR67jGpM6jSJbRriwbJjh2YNSZQmgvJ3-KNcp2mh6iQEUqQ8xI5l59j33Pj6XIReU6YCzxfUprF0baZCactQwmIoAun7CVxt_pTJiX90zo4vvcvfUZX6SsbOrOp_XOSinOv-oahF__Rw3N4N3T4-iPpQxh4wGwybU6pkB-36ZnOph3bPT05Hn9oTkDCLgQm3meXckNiw5HZbmszo1JpGWvHOAXOoQwjdMEo7eZVcxze3wyZvNXkpFt9Elv1hk8Z30efVyZ5lKMrMaWrpxD-2hR7_o7v30J2OquLRElv30Q2dP0A3J91m_EP0M1rnMMRFgqOLMX4TLeKsKKfFvJyKr6nS-xdpXlQ6k4bMevY4a4oK3iviNHuLRa5wNLmu1sTkta4r_R2Y8Fa1kbpqgP_X2IgddAfIFjjNcSvWjA9MmD08NHCuHqGz8fuz6Mjucj7YMfjKNViFMBBD6YZxEBIt1TBhFBiqnxgVURYOiQJCJzxX-W6iqJeIQchCGpAE3CY5JHQP9fIi108QVm6QMOUTGQOFITGVQvieFGAZNDGqeRZ6t_rmvFwqe3DwiAxAOAw5NwABx4hTDiNvoVeACj6LU270uM39S8FnFQev4wNnoR-QgYXwCjMc5qjZeBG5Lpo5NyEwhju7Fnq8hNC6RULMqup6FhpugGtdwDS3-SRPp60MOCUt_7bQ_hqGf-_I038q_QzdXv5DNzF1z1Gvrhr9AkhYLV92s-0Xl78s8Q |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparison+of+CVF+%28Cyclophosphamide%2BVinorelbine%2B5-Fluorouracil%29+and+CMF+%28Cyclophosphamide%2BMethotrexate%2B5-Fluorouracil%29+Adjuvant+Chemotherapy+in+Early+Breast+Cancer&rft.jtitle=Journal+of+breast+cancer&rft.au=Gwak%2C+Geumhee&rft.au=Park%2C+Kyeongmee&rft.au=Shin%2C+Eunah&rft.au=Han%2C+Sehwan&rft.date=2011-09-01&rft.issn=2092-9900&rft.eissn=2092-9900&rft.volume=14&rft.issue=3&rft.spage=223&rft_id=info:doi/10.4048%2Fjbc.2011.14.3.223&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1738-6756&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1738-6756&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1738-6756&client=summon |